Zhejiang AngLiKang Pharmaceutical Subsidiary Receives Approval for Finasteride API

MT Newswires Live

02/14

Zhejiang AngLiKang Pharmaceutical (SHE:002940) said its subsidiary, Hunan Kerui Biopharmaceutical, received approval from China's National Medical Products Administration for its Finasteride active pharmaceutical ingredient, according to a Thursday filing with the Shenzhen bourse.

Finasteride is used for benign prostatic hyperplasia (BPH) and male pattern baldness. The approval, valid until Feb. 11, 2030, allows the company to proceed with production and sales pending GMP compliance confirmation. This approval expands Anglikang's API portfolio.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2511632395"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2511632395\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2511632395?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-14 14:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2511632395","market":"nz","top_or_hot":-1,"title":"Zhejiang AngLiKang Pharmaceutical Subsidiary Receives Approval for Finasteride API","media":"MT Newswires Live","content":"<html><body><p> Zhejiang AngLiKang Pharmaceutical (SHE:002940) said its subsidiary, Hunan Kerui Biopharmaceutical, received approval from China's National Medical Products Administration for its Finasteride active pharmaceutical ingredient, according to a Thursday filing with the Shenzhen bourse.</p><p>Finasteride is used for benign prostatic hyperplasia (BPH) and male pattern baldness. The approval, valid until Feb. 11, 2030, allows the company to proceed with production and sales pending GMP compliance confirmation. This approval expands Anglikang's API portfolio.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang AngLiKang Pharmaceutical Subsidiary Receives Approval for Finasteride API</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang AngLiKang Pharmaceutical Subsidiary Receives Approval for Finasteride API\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-02-14 14:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Zhejiang AngLiKang Pharmaceutical (SHE:002940) said its subsidiary, Hunan Kerui Biopharmaceutical, received approval from China's National Medical Products Administration for its Finasteride active pharmaceutical ingredient, according to a Thursday filing with the Shenzhen bourse.</p><p>Finasteride is used for benign prostatic hyperplasia (BPH) and male pattern baldness. The approval, valid until Feb. 11, 2030, allows the company to proceed with production and sales pending GMP compliance confirmation. This approval expands Anglikang's API portfolio.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OTX.SI","symbol_name":"邁怡匯有限公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2511632395","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2511632395","pubTimestamp":1739515964,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zhejiang AngLiKang Pharmaceutical  said its subsidiary, Hunan Kerui Biopharmaceutical, received approval from China's National Medical Products Administration for its Finasteride active pharmaceutical ingredient, according to a Thursday filing with the Shenzhen bourse.Finasteride is used for benign prostatic hyperplasia  and male pattern baldness. The approval, valid until Feb. 11, 2030, allows the company to proceed with production and sales pending GMP compliance confirmation. This approval expands Anglikang's API portfolio.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OTX.SI":"迈怡汇有限公司","BK0239":"医药制造","002940":"昂利康","BPH":"BP P.L.C. ADRhedged","BPH.AU":"BPH ENERGY LTD","BK7048":"生命科学工具和服务","BK7062":"资产管理与托管银行"},"translate_title":"浙江昂利康药业子公司非那雄胺原料药获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OTX.SI":1,"BPH":1,"BPH.AU":1,"002940":0.9},"content_text":"Zhejiang AngLiKang Pharmaceutical (SHE:002940) said its subsidiary, Hunan Kerui Biopharmaceutical, received approval from China's National Medical Products Administration for its Finasteride active pharmaceutical ingredient, according to a Thursday filing with the Shenzhen bourse.Finasteride is used for benign prostatic hyperplasia (BPH) and male pattern baldness. The approval, valid until Feb. 11, 2030, allows the company to proceed with production and sales pending GMP compliance confirmation. This approval expands Anglikang's API portfolio.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}